ERBB2 and breast cancer: Notably, recent work identified enrichment of immunosuppressive immature myeloid cells (IMC) in anti-Her2 and CDK4/6 inhibitor-resistant HER2-positive breast cancer, while combinatorial treatment with cabozantinib (IMC-targeting tyrosine kinase inhibitor) and immune checkpoint blockade overcame resistance [201].